TO THE EDITOR
Severe Congenital Neutropenia (SCN), also referred to as Kostmann's syndrome, is a rare inherited disorder characterized by a profound neutropenia linked to a maturation arrest of myeloid progenitors at the promyelocyte stage and an elevated prevalence (9%) of MDS/AML transformation. 1 A group of five acquired nonsense mutations (codons 716, 718, 720, 726 and 731) clustering in the median part of the intracellular domain of the G-CSF receptor (G-CSF-R) has been reported in SCN patients, mainly in those developing secondary MDS or AML. 2, 3 All these mutations are C/T transitions introducing a STOP codon resulting in the deletion of the distal intracellular region of the G-CSF-R known to be involved in differentiation signaling. 4 Owing to the tight correlation noted between mutation occurrence and leukemic events in SCN patients, 2 the acquisition of these G-CSF-R mutations is suspected to be an important step in the leukemogenesis. Overall, 101 SCN patients have been enrolled in the French neutropenia registry, of whom six developed myelodysplasia/acute leukemia. During the course of G-CSF-R mutation screening in SCN patients of the French Neutropenia Registry, four patients were tested at the time they developed secondary malignant transformation. SCN was diagnosed according to previously described criteria (persistent profound neutropenia at a young age together with a maturation arrest of bone marrow myeloid progenitors).
1 Total RNA isolated from bone marrow mononuclear cells using the RNAplus reagent (Qbiogen, Illkirch, France) was reverse transcribed and submitted to PCR amplification between nucleotides 2310 and 2530, a fragment encompassing all the previously reported mutations, with forward primer 5 0 -GCTCA-GAGACCTGTGGCCTCCC-3 0 and reverse primer 5 0 -ATAG-GACTTGGGGCTGGGGGT-3 0 . PCR products were analyzed by (1) SSCP analysis performed at 201C in 12.5% polyacrylamide gels on a Genephor apparatus (Pharmacia Biotech), followed by a sensitive coloration with the DNA Silver Staining kit (Amersham Biosciences, Uppsala, Sweden), (2) restriction enzyme analysis with BfaI enzyme and (3) direct sequencing of purified PCR products. The nucleotide numbering is given according to the reference sequence whose accession number is gb:M59818.
Patient 1 (UPN 233015168), a girl with SCN diagnosed at 5 months old, was tested at 4 years of age when she developed an AML cytogenetically characterized by 46,XX, [2] /45,XX,-7 [19] . No G-CSF-R mutation was detected in this patient, both by SSCP, restriction analysis and direct sequencing of PCR products. The absence of mutation has been confirmed on DNA for this patient.
Patient 2 (UPN 233015200) had a SCN diagnosed at 2 months old. In this boy, G-CSF treatment was introduced at 4 months old and was continued until he developed a secondary MDS cytogenetically characterized by 45,XY,del(6)(q21),-7[15]/ 46,XY [5] at 9 years of age. The detected mutation, previously described in an SCN patient with secondary AML, 2 consisted of a C/T transition at nucleotide c.2396C4T, introducing a STOP codon at position 720 (Q720X).
Patient 3 (UPN 133015213) was a boy in whom SCN has been diagnosed at 2 months old. G-CSF treatment was initiated when he was 3 years old and continued until 8 years of age when he developed MDS/AML cytogenetically characterized by 47,XY,À7, þ 21, þ 21 [9] /46,XY [5] . At this time, we detected a previously reported 5 C/T transition at nucleotide c.2390C4T introducing a STOP codon at position 718 (Q718X).
Patient 4 (UPN 233015129), a girl in whom SCN was diagnosed a few days after birth, was continuously treated by G-CSF from 5 years of age until 12 years of age, when she developed a secondary acute lymphoblastic leukemia (ALL) cytogenetically characterized by 48,XX,del(5)(q21q34), þ 21, þ 22(16)/46,XX [8] . ALL was diagnosed on the blast cells morphology (61% in peripheral blood, 75% in the bone marrow), MPO negativity and immunophenotyping, consistent with the diagnosis of a pre-B ALL:
þ HLA-DR þ and CD2À, CD3À, CD7À, CD10À, CD13À, CD15À, CD20À, CD41À and CD61À. No fusion gene (BCR-ABL, TEL-AML1, MLL-AF4, E2A-PBX) was identified by RT-PCR on diagnostic samples. In addition, as already reported on ALL blasts and lymphocytes, 6 ,7 G-CSF-R was detected on ALL blasts of our patient. The patient reached complete cytogenetic remission following induction therapy associating corticosteroids, vincristine and daunorubicin. Consolidation therapy associated courses of dexamethasone plus high-dose araC and courses of prednisolone, vincristine, methotrexate, cyclophosphamide and adriamycine. The patient remains in complete remission after cord blood allogeneic transplantation. To our knowledge, only one other case of ALL secondary to SCN has been reported so far. 8 Together with a slight phenotype difference (CD20 and CD22 positivity of the blasts), the previous observation mainly differed from ours in the type of G-CSF-R mutation detected. Whereas the previous ALL case harbored two mutations in positions 718 and 726 also reported in MDS/AML cases, our case revealed a novel mutation as yet unpublished. It was a C/T transition introducing a STOP codon at position c.2342C4T (Figure 1a ), located upstream of other previously reported mutations (Figure 1c ), leading to a truncation at position 702 of the G-CSF-R amino-acid sequence (Q702X). The important consequence of this novel observation is that the deleted fragment encompasses all of the intracellular tyrosine residues (Y704, Y729, Y744 and Y764).
Our observation confirms that the majority, but not all, of SCN cases that transform (75% in the International Registry and in our study) have detectable G-CSF-R mutations. 9 Furthermore, as already reported, 1 monosomy 7 is a frequent event in secondary transformation of SCN as three out of the four patients presented here exhibited this anomaly. Of note, the ALL case did not present with a monosomy 7. Previous studies always reported the presence of both wild-type and mutated G-CSF-R sequences in patients' cells, 3, 5 and direct sequencing graphs suggested that this was also the case in our study (Figure 1a ). Of note, germline DNA could be analyzed in two out of the three mutated cases and no mutation was found.
The mechanisms inherent to the leukemogenesis in SCN are still unclear. Intracellular consequences of G-CSF-R mutations are supposed to be mainly dependent on their ability to activate distinct transduction pathways through tyrosine residues 4 that have been shown to be crucial in G-CSF signaling. 10 Indeed, each of the tyrosines is involved in the activation of specific signaling pathways through the binding of specific signaling proteins. As mutants may have different functional consequences depending on the number of residual tyrosine residues present in their sequence, It could be considered that previously reported G-CSF-R mutants are heterogeneous. Indeed (Figure 1c) , they could harbor either Y704, or Y704 and Y729, making it unlikely that they activate identical intracellular pathways. This raises the question of the equivalence of distinct G-CSF-R mutants for the development of secondary transformation. Our observation is the first of a mutation deleting all of the tyrosine residues, further pointing to the heterogeneity of G-CSF-R mutational events in SCN, and the complexity of its consequences both in terms of intracellular signalling, stem cell context and leukemogenesis.
Acknowledgements
This work has been supported by grants from the Association pour le Recherche contre le Cancer, and from AFM-Inserm network. . RANKL stimulates osteoclast differentiation and activity, and inhibits osteoclast apoptosis; these actions result in enhanced bone resorption. OPG binds to RANKL and prevents RANKL/RANK interaction.
1 Myeloma plasma cells have been found to increase RANKL expression and to decrease OPG availability in the bone microenvironment, yielding an increase of the osteoclastogenic signal as a consequence of increased RANKL/OPG ratio. 1 OPG circulates in peripheral blood under various forms, in complexes with soluble RANKL besides a free, nonbound portion. The heterogeneity of these circulating forms may account for discrepancies of absolute values reported in the literature. As far as patients with MM are concerned, serum levels of OPG have been repeatedly found to be decreased with respect to healthy controls, 2,3 the levels in the blood stream were found to be correlated with those in the bone marrow plasma. 4 To the best of our knowledge, no data are available on patients with MGUS and MM as a function of treatment. The aim of the present cross-sectional study was to investigate serum levels of OPG in a large group of MGUS and MM patients and in a 1:1, sex-and age-matched population of healthy controls.
A total of 103 MM patients (66 men and 37 women) and 37 MGUS (19 men and 18 women) were included in the study. Patients were diagnosed according to the criteria by Kyle et al. In all, 140 age-and sex-matched healthy subjects (84 men and 56 women) were recruited as controls among blood donors (up to 65 years of age) and people attending a light physical training program (over 65 years of age). None of the controls were receiving medications or had medical conditions known to affect bone metabolism.
In patients with MM, the following parameters were examined: Durie and Salmon stage, clinical and/or radiological evidence of presence of bone disease, calcemia, serum b 2 -microglobulin, phase of disease (at onset or under treatment), therapy with bisphosphonates. Characteristics of MM patients were as follows: median age 57 (32-82) years; 43 patients were in stage I, 15 in stage II, and 45 in stage III; 48 showed lytic lesions; 39 patients were at onset and 64 under treatment; 32 patients were treated with pamidronate at 90 mg intravenously every 4 weeks.
Serum of all patients were drawn between 1997 and 2003 and frozen at À701C to be analyzed later. OPG serum concentrations were measured by an ELISA developed in our laboratory using commercially available reagents (OPG DuoSet, R&D Systems, Abingdon, UK), according to the manufacturer's instructions and previously published results. 5 Capture antibody was a monoclonal mouse anti-human OPG; detection antibody was a biotinylated goat polyclonal anti-human OPG. Reagent diluent was PBS with 50% FCS and 1% BSA. Analytical performance parameters were as follows: range: 62.5-4000 pg/
